{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7"},{"groupId":"OG001","value":"8.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"205"}],"units":"Participants"}],"groups":[{"description":"Eight cycles of rituximab IV infusion (375 mg/m\\^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\\^2) once every 8 weeks for 24 months.","id":"OG000","title":"Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)"},{"description":"First cycle of rituximab IV infusion (375 mg/m\\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.","id":"OG001","title":"Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)"}],"paramType":"NUMBER","populationDescription":"ITT population.","reportingStatus":"POSTED","timeFrame":"Baseline up to death (up to data cutoff of 31 Oct 2017 [up to 6 years])","title":"Percentage of Participants Who Died","type":"SECONDARY","unitOfMeasure":"percentage of participants"}